PO Box 9162
Department of Medicine
Section of Hematology/ Oncology
3rd Floor Cancer Center, Room 3935
- West Virginia University School of Medicine
- Hematology / Oncology
- West Virginia University WVU Cancer Institute
- WVU Cancer Institute Clinics
- MD, University of Damascus School of Medicine
Peer-Reviewed Journal Publications:
Wise-Draper TM, Moorthy G, Salkeni MA, Karim NA, Thomas HE, Mercer CA, Beg MS, O’Gara S, Olowokure O, Fathallah H, Kozma SC, Thomas G, Rixie O, Desai P, Morris JC. A Phase lb Study of the Dual Pl3K/mTOr inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies. Target Oncol. 2017 Mar 29. Dol: 10.1007/s11523-017-0482-9, [Epub ahead of print]
Vahdat LT, Layman R, Yardley DA, Gradishar W, Salkieni MA, Joy AA, Garcia AA, Ward P, Khatcheressian J, Sparano J, Rodriguez G, Tang S, Gao L, Dalal RP, Kauh J, Miller K. Randomized phase ll Study of Ramucirumab in Combination Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer. Oncologist. 2017 Mar;22(3):245-254. doi: 10.1634/theoncologist.2016-0265. Epub 2017 Feb 20.
Kozyreva VK, Kiseleva A, Ice RJ, Jones BC, Loskutov YV, Matalkah F, Salkeni MA, et al. Combination of Eribulin and Aurora A inhibitor MLN8237 prevents metastatic colonization and induces cytotoxic autophagy in breast cancer. Molecular cancer therapeutics. 2016 May 27. Epublished ahead of print.
Farrugia MK, Vanderbilt DB, Salkeni MA, Ruppert JM. Kruppel-like Pluripotency Factors as Modulators of Cancer Cell Therapeutic Responses. Cancer research. 2016 Apr 1;76(7):1677-82
Jacobson GM, Partin JF, Salkeni MA. Optimal management of sentinel lymph node positive biopsy patients in early breast cancer. Annals of translational medicine. 2015 May;3(7):87.
Farrugia MK, Sharma SB, Lin CC, McLaughin SL, Vanderbilt DB, Ammer AG, Salkeni MA, et al. Regulation of anti-apoptotic signaling by Kruppel-like factors 4 and 5 mediates lapatinib resistance in breast cancer. Cell death & disease. 2015 Mar 19;6:e1699.
Alsubait S, Deeb A, Zimmermann N, Bhaskaran J, Salkeni MA. Resolution of Telangiectasia Macularis Eruptiva Perstans with Successful Treatment of Synchronous Large Granular Lymphocytic Leukemia. Ann Hematol Oncol. 2015;2(7): 1052.
Sharma SB, Lin CC, Farrugia MK, McLaughin SL, Ellis EJ, Brundage KM, Salkeni MA, et al. MicroRNAs 206 and 21 cooperate to promote RAS-extracellular signal-regulated kinase signaling by surpressing the translation of RASA1 and SPRED1. Molecular and Cellular Biology. 2014 Nov 15;34(22):4143-64.
Salkeni MA, Zarzour A, Ansay TY, McPherson CM, Warnick RE, Rixe O, et al. Detection of EGFRvlll mutant DNA in the peripheral blood of brain tumor patients. J Neurooncol. 2013 Oct;115(1):27-35
Patel D, Salkeni M, Chaudhary R. Bevacizumab and Glloblastoma Multiforme: A Thrombosis and Bleeding Dilemma (A Case Report and a Brief Review of the Literature). Am J Ther. 2013 Apr 11.
Salkeni MA, Lynch JL, Otamis-Price T, Bank WA. Lipopolysaccharide impairs blood-brain barrier P-glycoprotein function in mice through prostaglandin- and nitric oxide-independent pathways. J Neuroimmune Pharmacol. 2009 Jun;4(2):276-82.
AACR/ASCO Joint Workshop, Methods in Clinical Cancer Research. Vail, Colorado, July 23-29, 2016. ISS: “ A dose escalation, single arm, phase lb/ll study of alisertib (MLN8237) in combination with eribulin to determine the maximum tolerated doses, safely and activity in patients with advanced solid tumors and breast cancer”.
NCTN High Performance Site Initiative Award to WVU, January 2017. NCI awarded $35,200 to support infrastructure of member institutions/sites that participate on NCTN with significant clinical trial accruals and data quality. Salkeni was selected to coordinate and facilitate payment.
NRG voting member privileges 2014-present: WVU granted voting number privileges for the first time since acquiring membership.
Best senior resident talk titled: “Lipopolysaccharide Impairs Blood-brain Barrier P-glycoprotein Function in Mice Through Prostaglandin- and Nitric Oxide-independent Pathways”. Saint Louis University. St. Louis MO. 2009.
Fourth and fifth year medical school Award of Excellence (ranked third and second in class, respectively). Damascus, Syria. 2002 & 2003 (award granted to top 3 students in each class of medical school).
Professional Societies Membership:
American Association of Cancer Research (AACR). Member since 2016
West Virginia State Medical Association (WVSMA). Member since 2016
West Virginia State Oncology Society (WVOS). Member since 2013
American Society of Clinical Oncology (ASCO). Member since 2010
American Society of Hematology (ASH) Member since 2010
About Mohamad Adham Salkeni
Mohamad Adham Salkeni, MD is an Associate Professor of Medicine and Medical Director of the Clinical Trials Research Unit at the West Virginia University (WVU) School of Medicine in Morgantown, West Virginia.
Dr. Salkeni earned a Doctor of Medicine Diploma (M.D.) degree from the University of Damascus, Syria. He completed postgraduate residency training in Internal Medicine at St Louis University School of Medicine, MO; then he completed a fellowship training in Hematology and Medical Oncology at the University of Cincinnati, OH.
Dr. Salkeni is board-certified in Internal Medicine, Hematology, and Medical Oncology by the American Board of Internal Medicine. Since completing his training, he has maintained a continuous clinical practice at West Virginia University Hospital and the Mary Babb Randolph Cancer Center.
Dr. Salkeni has devoted his academic career to caring for breast cancer patients. He leads several clinical trials of novel cancer therapies at WVU. In addition, Dr. Salkeni participates in training and teaching of medical students, internal medicine residents and oncology fellows. He is also interested in improving the delivery of clinical trials to cancer patients in the state of West Virginia through the WV Clinical Trials Network.
Recognized for his work in clinical research, Dr. Salkeni was appointed as the Medical Director for the Clinical Trials Research Unit. Dr. Salkeni in an active member in the American Society of Clinical Oncology, American Society of Hematology, American Association of Cancer Research, and West Virginia Oncology Society.
I recently joined the faculty of WVU School of Medicine in December 2012 upon completing my fellowship training at the University of Cincinnati. My clinical interests mainly focuses on breast cancer and phase I trials of novel agents in solid tumors. During my fellowship at the University of Cincinnati I participated in numerous phase I studies under the direction of Dr. Olivier Rixe, a leader in the field of experimental therpeutics. Agents that I worked with included: AMG595, a novel antibody-drug conjugate against EGFRvIII in malignant gliomas; BEZ235, a dual mTOR/PI3K inhibitor; SAR650984, a CD38+ monoclonal antibody; MM-121; XRP6258 (cabazitaxel); SAR566658; among others. I have also participated in writing up investigator initiated clinical trials that are currently open and accruing. My main goal to be a bridge that connects bench research to bedside or clinic
Grants and Research
Agency: WVCTSI Pilot grant (West Virginia Clinical & Translational Science Institute). ID#: Intramural grant. Title: Pre-clinical studies to determine efficacy of Aurora A (AURKA) kinase inhibitor MLN8054 in prevention and treatment of breast cancer metastasis using patient-derived tumors. PI: Elena Pugacheva, PhD. Role: Co-investigator and clinical collaborator. Period: 60/15/2013-06/14/2014. Amount: $50,000. Description: The goal is to evaluate the current findings of anti-metastatic activity of AURKA inhibitors in xenograft models of transplanted late stage (lll-lV) patient-derived breast tumors to establish patient-derived tumor xenografts and assess expression of AURKA, define the impact of AURKA expression in patient tumors and examine the efficacy of AURKA inhibitors for metastasis prevention or/and treatment.
Agency: WVCTSI Pilot grant (West Virginia Clinical & Translational Science Institute). ID#: Intramural grant. Title: Kruppel-like factors in resistance to HER2-targeted therapy. PI: J Michael Ruppert, PhD. Role: Co-investigator and clinical collaborator. Period: 06/01/2015-05/31/2016. Amount: $50,000. Description: Cancer therapy has risks including cognitive effects and the induction of new malignancies. There is need for stratification of patients so as to avoid unnecessary therapy and to enable more aggressive therapy of higher risk tumors. Our studies identify a rational approach for stratifying high and low risk, HER2+ breast cancer patients and for designing novel therapeutic combinations that will potentiate anti-HER2 therapy.
Agency: University of Cincinnati Neuroscience Foundation. ID#: Intramural grant. Title: New biomarkers of GBM tumors using whole-genome sequencing. PI: El Mustapha Bahassi, PhD. Role: Co-investigator(>50% effort). Period: 07/01/2011-60/30/2013. Amount: $50,000.
Agency: CCTST Pilot grant (Center for Clinical & Transitional Science & Training). ID#: Intramural grant. Title: Circulating tumor DNA to monitor Brain Tumor Dynamics. PI: El Mustapha Bahassi, PhD. Role: Co-investigator (>50% effort). Period: 03/1/13-02/30/14. Amount: $100,000.
Patient Care Information
- Cancer / Oncology
- Hematology/Oncology (Cancer)
- Medical Oncology (Cancer)
- Medical Oncology, American Board of Internal Medicine
- Internal Medicine, American Board of Internal Medicine
- Hematology, American Board of Internal Medicine
Residency, Internal Medicine
Saint Louis University School of Medicine, 2009
Fellowship, Hematology and Medical Oncology
University of Cincinnati, 2012